ReviewFrontiers in microbiology2017
UroPathogenic
Review in Frontiers in microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 357 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
357 citing papers in PubMed, 2 syntheses or guidelines pooled it, 679 citations in OpenAlex.
- Recurrent urinary tract infection genetic risk: a systematic review and gene network analysis.International urogynecology journal · 2024Pooled it
- One Health Determinants ofInternational journal of molecular sciences · 2023Pooled it
- A 14-Day Double-Blind, Randomized, Controlled Crossover Intervention Study with Anti-Bacterial Benzyl Isothiocyanate from Nasturtium (Nutrients · 2024Trial
- Article
- Urinary Tract Infections: Molecular Determinants of Uropathogenicity and Their Translation into Contemporary Clinical Practice.International journal of molecular sciences · 2026Review
- Rational Design of a Phage Cocktail for Effective Control of Multidrug-Resistant UropathogenicAntibiotics (Basel, Switzerland) · 2026Article
- Characterisation of Haemolytic Uropathogenic Escherichia coli Isolated From Dogs and Cats.Veterinary medicine and science · 2026Article
- First Randomized Controlled Trial Comparing D-Mannose to Fosfomycin in Acute Uncomplicated Lower Urinary Tract Infections.Antibiotics (Basel, Switzerland) · 2026Article
- Distribution of Uropathogens and Molecular Characterisation of Virulence Genes of UropathogenicPathogens (Basel, Switzerland) · 2026Article
- Article
- Cytolethal distending toxin enhancesInfection and immunity · 2026Article
- Development andMicrobiology spectrum · 2026Article
- Detection of intracellular bacterial communities and biofilms in urinary tract infections withWorld journal of experimental medicine · 2026Article
- Antimicrobial efficacy of carbon nanotube-based nano drug onBiochemistry and biophysics reports · 2026Article
- Effectiveness of Individualized Autovaccine Immunotherapy in Women With Recurrent Urinary Tract Infections: A Prospective Cohort Study.Open forum infectious diseases · 2026Article
- Long-chain fatty acid homeostasis contributes to survival of uropathogenicJournal of bacteriology · 2026Article
- Host range and zoonotic potential linked to P-like fimbrial (PLF) adhesin specificity in avian pathogenic Escherichia coli.PLoS pathogens · 2026Article
- Global survey of extraintestinal pathogenic Escherichia coli identifies stable serogroup-virulence-resistance linkages.Genome medicine · 2026Article
- An update on Escalating Drug Resistance among Uropathogenic Bacteria: Challenges in Treatment and Scope for Maneuver.Current microbiology · 2026Review
- Prophylactic Potential ofMicroorganisms · 2026Article
297 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urinary tract infections (UTIs) are one of the most common pathological conditions in both community and hospital settings. It has been estimated that about 150 million people worldwide develop UTI each year, with high social costs in terms of hospitalizations and medical expenses. Among the common uropathogens associated to UTIs development, UroPathogenic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.